You are here

Publications

Found 32 results
[ Author(Desc)] Title Type Year
Filters: First Letter Of Last Name is N  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
N
Na SY, Kang BY, Chung SW, Han SJ, Ma X, Trinchieri G, Im SY, Lee JW, Kim TS.  1999.  Retinoids inhibit interleukin-12 production in macrophages through physical associations of retinoid X receptor and NFkappaB.. J Biol Chem. 274(12):7674-80.
Nathan C, Nussenzweig MC, Pulvirenti T.  2017.  JEM Advisory Editorial Board: Increasing diversity.. J Exp Med.
Nathan C, Ding A.  2010.  Nonresolving inflammation.. Cell. 140(6):871-82.
Nathan C.  2013.  A journey in science: promise, purpose, privilege.. Mol Med. 19(1):305-13.
Nathan C.  2002.  Points of control in inflammation.. Nature. 420(6917):846-52.
Nathan C.  2017.  Kunkel Lecture: Fundamental immunodeficiency and its correction.. J Exp Med. 214(8):2175-2191.
Nathan C.  2017.  Introduction of Laurie H. Glimcher, MD.. J Clin Invest. 127(10):3575.
Nathan CF, Nussenzweig MC, Pulvirenti T.  2019.  JEM Editorial Board: Expanding on the basis of cancer.. J Exp Med. 216(8):1725.
Nathan C.  2009.  Taming tuberculosis: a challenge for science and society.. Cell Host Microbe. 5(3):220-4.
Nathan C, Cars O.  2014.  Antibiotic resistance--problems, progress, and prospects.. N Engl J Med. 371(19):1761-3.
Nathan C, Calingasan N, Nezezon J, Ding A, M Lucia S, La Perle K, Fuortes M, Lin M, Ehrt S, Kwon NSoo et al..  2005.  Protection from Alzheimer's-like disease in the mouse by genetic ablation of inducible nitric oxide synthase.. J Exp Med. 202(9):1163-9.
Nathan C, Nussenzweig M, Pulvirenti T.  2017.  The new face of JEM.. J Exp Med. 214(12):3467.
Nathan C.  2007.  Aligning pharmaceutical innovation with medical need.. Nat Med. 13(3):304-8.
Nathan C.  2015.  Cooperative development of antimicrobials: looking back to look ahead.. Nat Rev Microbiol. 13(10):651-7.
Nathan C.  2006.  Neutrophils and immunity: challenges and opportunities.. Nat Rev Immunol. 6(3):173-82.
Nathan C, Barry CE.  2015.  TB drug development: immunology at the table.. Immunol Rev. 264(1):308-18.
Nathan C.  2020.  Resisting antimicrobial resistance.. Nat Rev Microbiol. 18(5):259-260.
Nathan C.  2012.  Fresh approaches to anti-infective therapies.. Sci Transl Med. 4(140):140sr2.
Nathan C.  2004.  Antibiotics at the crossroads.. Nature. 431(7011):899-902.
Nathan C.  2015.  What can immunology contribute to the control of the world's leading cause of death from bacterial infection? Immunol Rev. 264(1):2-5.
Naureckiene S, Holloman WK.  1999.  DNA hydrolytic activity associated with the Ustilago maydis REC1 gene product analyzed on hairpin oligonucleotide substrates.. Biochemistry. 38(43):14379-86.
Negri A, Javidnia P, Mu R, Zhang X, Vendome J, Gold B, Roberts J, Barman D, Ioerger T, Sacchettini JC et al..  2018.  Identification of a Mycothiol-Dependent Nitroreductase from Mycobacterium tuberculosis.. ACS Infect Dis. 4(5):771-787.
Neveu G, Beri D, Kafsack BFc.  2020.  Metabolic regulation of sexual commitment in Plasmodium falciparum.. Curr Opin Microbiol. 58:93-98.
Nicolás AL, Munz PL, Falck-Pedersen E, Young CS.  2000.  Creation and repair of specific DNA double-strand breaks in vivo following infection with adenovirus vectors expressing Saccharomyces cerevisiae HO endonuclease.. Virology. 266(1):211-24.
Niederweis M, Ehrt S, Heinz C, Klöcker U, Karosi S, Swiderek KM, Riley LW, Benz R.  1999.  Cloning of the mspA gene encoding a porin from Mycobacterium smegmatis.. Mol Microbiol. 33(5):933-45.